Big Pharma Split Corp Class A Cash Flow Reinvestment Rate
Big Pharma Split Corp Class A cash flow reinvestment rate. Big Pharma Split Corp Class A (PRM) has a Cash Flow Reinvestment Rate of 0.00x as of September 2023, reinvesting CA$0.00 (capex CA$0.00 ) from operating cash flow of CA$644.28K. Explore Big Pharma Split Corp Class A cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Big Pharma Split Corp Class A (2018–2023)
Cash flow reinvestment rate of Big Pharma Split Corp Class A from 2018 to 2023. Historical reinvestment intensity for Big Pharma Split Corp Class A across 5 annual periods. Explore PRM capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.
Big Pharma Split Corp Class A Cash Flow Reinvestment Rate by Year (2018–2023)
Big Pharma Split Corp Class A cash flow reinvestment rate by year from 2018 to 2023. Year-by-year capital reinvestment analysis for Big Pharma Split Corp Class A. For the full cash flow conversion analysis, see PRM operating cash flow.
| Year | Reinvestment Rate | Total Reinvested (CAD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.00x | CA$3.00 | CA$11.86 Million | CA$3.00 | — |
| 2022 | 0.00x | CA$0.00 | CA$1.13 Million | CA$0.00 | ▼ -100.0% |
| 2020 | 0.00x | CA$3.00 | CA$4.35 Million | CA$3.00 | — |
| 2019 | 0.00x | CA$0.00 | CA$8.68 Million | CA$0.00 | — |
| 2018 | 0.00x | CA$0.00 | CA$1.27 Million | CA$0.00 | — |